
Medicine and Health
Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader
A. V. Carmona, S. Jonnalagadda, et al.
Discover the groundbreaking research by Angelica V. Carmona and colleagues on the first-in-class AKR1C3 PROTAC degrader that shows promise in targeting prostate cancer by reducing AKR1C3 expression and degrading ARv7. This innovative approach could change the landscape of prostate cancer treatment.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.